Although not previously reported in PC, this mutation has been found in glioblastoma; it occurs in the extracellular domain and results in increased basal EGFR phosphorylation targetable by erlotinib.14,15 This is distinct from the activating kinase domain mutations seen in lung adenocarcinoma. This evidence concerns the gene EGFR and glioblastoma.